Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
TBN
4551
Tamboran Resources
TBN
$1.18B
| $81.4K | ﹤0.01% |
2,990
-956
| -24% | -$24.3K |
2025 Q2
2 quarters
|
|
4552
CALL
Takeda Pharmaceutical
TAK
$57.1B
| $81.1K | ﹤0.01% |
+5,200
| New | +$74.3K |
2025 Q4
0 quarters
|
|
|
ALMS
4553
PUT
Alumis Inc
ALMS
$887M
| $81K | ﹤0.01% |
+8,300
| New | +$57.9K |
2025 Q4
0 quarters
|
|
4554
Urban One Class A
UONE
$18.4M
| $80.8K | ﹤0.01% |
7,841
+810
| +12% | +$9.96K |
2022 Q2
14 quarters
|
|
|
PAAI
4555
Paradium.AI, Inc.
PAAI
$55.2M
| $80.5K | ﹤0.01% |
20,135
+888
| +5% | +$3.98K |
2025 Q2
2 quarters
|
|
4556
FT Vest US Equity Deep Buffer ETF December
DDEC
$441M
| $80.5K | ﹤0.01% |
1,785
-2,814
| -61% | -$125K |
2024 Q3
5 quarters
|
|
4557
State Street SPDR S&P Semiconductor ETF
XSD
$3.25B
| $80.4K | ﹤0.01% |
250
| – | – |
2023 Q2
10 quarters
|
|
4558
NextCure
NXTC
$23.3M
| $79.8K | ﹤0.01% |
5,626
| – | – |
2019 Q2
26 quarters
|
|
|
TJAN
4559
Innovator Equity Defined Protection ETF - 2 Yr to January 2027
TJAN
$32.2M
| $79.8K | ﹤0.01% |
2,921
-79
| -3% | -$2.14K |
2025 Q3
1 quarter
|
|
4560
FirstService
FSV
$5.64B
| $79.8K | ﹤0.01% |
513
-44,134
| -99% | -$7.18M |
2020 Q3
21 quarters
|
|
4561
FT Vest US Equity Moderate Buffer ETF July
GJUL
$416M
| $79.4K | ﹤0.01% |
1,921
-3,046
| -61% | -$124K |
2024 Q3
5 quarters
|
|
4562
Innovator US Equity Power Buffer ETF May
PMAY
$816M
| $79.3K | ﹤0.01% |
2,004
-1,796
| -47% | -$70.3K |
2024 Q3
5 quarters
|
|
4563
Alvotech
ALVO
$1.94B
| $79.3K | ﹤0.01% |
15,459
-5,745
| -27% | -$36.3K |
2024 Q4
4 quarters
|
|
|
OKUR
4564
OnKure Therapeutics
OKUR
$104M
| $79K | ﹤0.01% |
27,242
+26,621
| +4,287% | +$79.7K |
2022 Q1
15 quarters
|
|
4565
OPAL Fuels
OPAL
$52.7M
| $78.6K | ﹤0.01% |
33,384
+3,156
| +10% | +$7.61K |
2025 Q2
2 quarters
|
|
4566
Siebert Financial
SIEB
$90.4M
| $77.9K | ﹤0.01% |
22,183
+2,207
| +11% | +$7K |
2025 Q2
2 quarters
|
|
|
SLSN
4567
Solesence Inc
SLSN
$57.9M
| $77.7K | ﹤0.01% |
48,744
-161
| -0.3% | -$436 |
2025 Q2
2 quarters
|
|
4568
Alpha Teknova
TKNO
$483M
| $77.3K | ﹤0.01% |
20,342
+336
| +2% | +$1.64K |
2024 Q4
4 quarters
|
|
|
LKFT
4569
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.92B
| $77K | ﹤0.01% |
2,355
-36,647
| -94% | -$1.18M |
2024 Q3
5 quarters
|
|
4570
Pharvaris
PHVS
$2.19B
| $77K | ﹤0.01% |
+2,775
| New | +$66.8K |
2025 Q4
0 quarters
|
|
4571
NLI Holdings
NL
$341M
| $76.9K | ﹤0.01% |
14,061
+1,282
| +10% | +$7.32K |
2016 Q3
37 quarters
|
|
|
SBC
4572
SBC Medical Group
SBC
$523M
| $76.6K | ﹤0.01% |
17,779
+9,831
| +124% | +$37.5K |
2025 Q2
2 quarters
|
|
|
SQMX
4573
FT Vest U.S. Equity Quarterly Max Buffer ETF
SQMX
$57.6M
| $76.5K | ﹤0.01% |
2,294
-3,496
| -60% | -$115K |
2025 Q1
3 quarters
|
|
|
AFCG
4574
AFC Gamma
AFCG
$78.6M
| $76.4K | ﹤0.01% |
26,794
+1,038
| +4% | +$3.3K |
2022 Q2
14 quarters
|
|
4575
Prairie Operating Co
PROP
$42.4M
| $76.1K | ﹤0.01% |
45,046
+13,953
| +45% | +$25.4K |
2024 Q2
6 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.